Rituximab leads to clinically important benefits in progression-free survival or overall survival in the following settings: Addition to combination chemotherapy for initial treatment of aggressive B-cell lymphomas. Addition to combination chemotherapy for initial and subsequent treatment of follicular lymphoma and other indolent B-cell lymphomas. Use as maintenance in patients with indolent B-cell lymphomas who have responded to chemo-immunotherapy. Addition to fludarabine-based chemotherapy or chlorambucil for initial treatment of chronic lymphocytic leukaemia.